Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Taunt

Adult Reconstructive Orthopaedic Surgery Lansing, MI Doctor of Osteopathy

NPI 1104816511 CMS profile 321803

2815 S Pennsylvania Ave, Ste 204, Lansing, MI 48910

Open in the dashboard

General payments

$126,431

146 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,150 paid to institutions, not to them · program year 2021

Through program year 2025, Charles Taunt of Lansing, MI is reported in the CMS Open Payments database as having received $126,431 across 146 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,150 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $440 7
2024 General $6,111 18
2023 General $20,613 19
2022 General $28,647 16
2021 General $21,914 22
2020 General $3,544 14
2019 General $45,162 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Taunt
  • Adult Reconstructive Orthopaedic Surgery median
  • Middle half of Adult Reconstructive Orthopaedic Surgery
  • National median

In program year 2025, general payments to Charles Taunt were reported at $440. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.

Show as a table
Year Charles Taunt Adult Reconstructive Orthopaedic Surgery median Middle half National median
2019 $45,162 $1,416 $292–$9,336 $163
2020 $3,544 $647 $141–$6,474 $114
2021 $21,914 $1,073 $211–$6,497 $132
2022 $28,647 $1,217 $236–$6,299 $149
2023 $20,613 $1,082 $246–$6,818 $160
2024 $6,111 $1,575 $323–$8,944 $164
2025 $440 $1,406 $318–$8,709 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Aesculap Implant Systems, LLC $115,444 55 payments
  2. Zimmer Biomet Holdings, Inc. $5,855 15 payments
  3. Aesculap AG $1,591 5 payments
  4. Stryker Corporation $657 7 payments
  5. Orthalign Inc $362 2 payments
  6. Abbott Laboratories $306 3 payments
  7. LinkBio Corp $271 1 payment
  8. Heron Therapeutics, Inc. $262 4 payments
  9. Amgen Inc. $255 3 payments
  10. Flexion Therapeutics, Inc. $184 11 payments
  11. Other $1,242 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $81,346 18 payments
  2. Travel and Lodging $33,542 19 payments
  3. Food and Beverage $5,948 108 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,595 1 payment
Products named General payments · program years 2019–2025
  1. NO CURRENT MARKETED PRODUCT NAME $36,585 6 payments
  2. Product Under Development - None $19,142 6 payments
  3. ORTHOPILOT $8,928 1 payment
  4. VEGA SYSTEM $5,924 6 payments
  5. ROSA $4,879 4 payments
  6. NO MARKETED PRODUCT NAME Ortho-Product Under Development $3,311 7 payments
  7. COLUMBUS CR $1,500 1 payment
  8. NO MARKETED PRODUCT NAME Orthopaedic Joint Replacement $887 3 payments
  9. COLUMBUS AS $807 4 payments
  10. AS VEGA SYSTEM PS $632 2 payments
  11. Other $4,975 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

1,044

Median for Orthopedic Surgery: 203

Drug cost

$7,956

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 161 $2,845
Mupirocin Generic 353 $2,165
Cephalexin Generic 332 $1,396
Minocycline Hcl Generic 22 $491
Oxycodone Hcl Generic 21 $365
Gabapentin Generic 37 $287
Clindamycin Hcl Generic 52 $187
Meloxicam Generic 52 $180
Ciprofloxacin Hcl Generic 14 $40

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$161,815

Of which drugs: $657

Medicare patients

278

Average age 74

Services billed

1,253

178 women, 100 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 27%
Diabetes 26%
Chronic kidney disease 22%
Osteoporosis 20%
Ischemic heart disease 19%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 26 105 $72
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 26 105 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $122
$122 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

146 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Reconstructive Orthopaedic Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record